New cocktail aims to tame myeloma without transplant
NCT ID NCT07601100
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) in 88 adults newly diagnosed with multiple myeloma who cannot or choose not to have a stem cell transplant. The goal is to find the safest dose and see how well the drugs control the cancer. Participants will be monitored for side effects and treatment response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time CAR-T therapy outsmart myeloma and replace lifelong treatment?
- New Four-Drug cocktail aims to wipe out Hard-to-Treat myeloma
- New cocktail of cancer drugs aims to wipe out myeloma before transplant
- New hope for frail myeloma patients: phase III trial tests smarter drug combos
- New drug combo aims to tailor myeloma treatment to each patient
- New hope for myeloma: experimental drug combo aims to beat standard care